Chagas Disease
Conditions
Keywords
Galectin-3, Chagas disease, Biomarkers
Brief summary
The purpose of this study is to analyze the efficacy of Galectin-3 as a biomarker on the Chagas Disease prognosis. This analysis will be done through the correlation between the plasmatic levels of this molecule with functional and laboratory tests.
Detailed description
Previous studies indicate that activated macrophages secrete Galectin-3, a molecule that is involved in the development of fibrosis and tissue rearrangement in the liver, kidney and the heart. Its plasmatic levels are increased on patients with acute decompensated heart failure. These observations suggest that measuring levels of Galectin-3 in patients with cardiac diseases can be useful to determine their prognosis. To investigate the role of this new biomarker in Chagas Disease, we will study a Chagas Disease population (including patients with the indeterminate and cardiac form of the disease). The assessment of the prognostic value of Galectin-3 will be done through the comparison between its plasmatic levels and each patients's clinical evaluation, disease severity, inflammatory biomarkers and cardiac function tests. The patients included in the study must at first sign the written consent. They shall be accompanied in the specialized outpatient clinics for Chagas disease - Hospital São Rafael - Centro de Biotecnologia e Terapia Celular. They will be submitted to several tests, including: * Collection of Blood samples for biochemical analysis; * Electrocardiogram; * Holter Electrocardiogram; * Echocardiogram; * Treadmill Test; * X-Ray Imaging; * Magnetic Resonance Imaging; * Evaluation of the quality of life through the application of questionnaires (SF 36 and the Minnesota Living With Heart Failure Questionnaire).
Interventions
None listed
Sponsors
Hospital Sao Rafael
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Chagas Disease diagnosis confirmed by 2 different serologies * Diagnosis of indeterminate form or cardiac form, with and without ventricular dysfunction.
Exclusion criteria
* Significant valve disease defined as aortic stenosis with a gradient of VE/Ao \> 50 mmHg * Mitral stenosis with a valve area inferior than 1,5 cm2 * Severe or moderate aortic and/or mitral regurgitation * Chronic use of immunosuppressive agents * Dialysis treatment of terminal renal failure * Fever on the last 48 hours or evidence of systemic infection in activity according to the definition of sepsis of the ACCP/SCCM (American College os Chest Physicians/Society of Critical Care Medicine) * Current abusive use of alcohol or illicit drugs (Based on the DSM IV) * Any other comorbidities that impact patient's survival within the next 2 years * Liver disease in activity * Continuous use of steroids as treatment for COPD * Hematologic, neoplastic or bone diseases * Homeostasis disturbances * Inflammatory diseases or chronic infectious diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of plasmatic levels of Galectin-3 with the percentage of heart fibrosis | One year | Mensuration of heart fibrosis percentage with Magnetic Resonance Imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of plasmatic levels of Galectin-3 with the functional capacity of the heart | One year | Mensuration of the functional capacity with treadmill test |
| Correlation of plasmatic levels of Galectin-3 with the serum levels of Pro-BNP. | One year | — |
| Correlation of plasmatic levels of Galectin-3 with the serum levels of TNF-alpha | One year | — |
| Correlation of plasmatic levels of Galectin-3 with the serum levels of IFN-gamma. | One year | — |
Countries
Brazil
Outcome results
None listed